All In Biotech

Drug Trial Radar · NCT06771271

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

A Multi-center, Non-Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination With Ranibizumab Following Intravitreal Administration in Patients With Diabetic or Uveitic Macular Edema

Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Jul 22, 2019

Primary completion

Nov 13, 2023

Study completion Nov 13, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema \[DME\] or uveitic macular edema \[UME\] population) and in combination with ranibizumab (DME population only).

Conditions

  • Diabetic Macular Edema
  • Uveitic Macular Edema

Interventions

  • RO7200220Drug

    RO7200220 was administered as IVT injection.

  • RanibizumabDrug

    Ranibizumab was administered as IVT injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to 18 weeks
  2. Part 2: Number of Participants With Adverse Events (AEs)Time frame: Up to 24 weeks
  3. Part 3: Number of Participants With Adverse Events (AEs)Time frame: Up to 20 weeks
  4. Part 4: Number of Participants With Adverse Events (AEs)Time frame: Up to 36 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • California Retina Consultants

    Oxnard, California

  • Retina Institute of California Medical Group d/b/a Acuity Eye Group

    Palm Desert, California

  • Byers Eye Insitute at Stanford

    Palo Alto, California

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Illinois Retina Associates SC

    Oak Park, Illinois

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Sierra Eye Associates

    Reno, Nevada

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon HSU

    Portland, Oregon

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Retina Res Institute of Texas

    Abilene, Texas

  • Austin Clinical Research LLC

    Austin, Texas

  • Valley Retina Institute P.A.

    McAllen, Texas

  • Medical Center Ophthalmology Associates

    San Antonio, Texas

  • Univ of Virginia Ophthalmology

    Charlottesville, Virginia

  • Karalis Johnson Retina Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.